CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults
CTSA 多样性补充 - Vielot - 重组带状疱疹疫苗对美国老年人的有效性
基本信息
- 批准号:10294412
- 负责人:
- 金额:$ 17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAddressAdjuvantAdolescenceAdolescentAdrenal Cortex HormonesAdultAdvisory CommitteesAgeAge-YearsAgreementAlgorithmsAnatomyApplications GrantsAreaAutoimmune DiseasesAutologousAwardBiologicalBiological ProductsBlack raceBlindnessCOVID-19 pandemicCOVID-19 vaccineCardiovascular DiseasesCaringCase StudyCenters for Disease Control and Prevention (U.S.)CharacteristicsChemicalsChickenpoxClassificationClinicalClinical ManagementClinical MedicineClinical ResearchClinical SciencesClinical TrialsCodeCohort StudiesCollaborationsCommunicable DiseasesCommunicationComparative Effectiveness ResearchConsultConsultationsCox ModelsCurrent Procedural Terminology CodesDataData AnalysesData CollectionData ScienceData SetData SourcesDatabasesDetectionDevelopmentDevelopment PlansDiabetes MellitusDiagnosisDisciplineDiseaseDisease-Modifying Second-Line DrugsDisseminated Malignant NeoplasmDoctor of PhilosophyDoseDrug IndustryDrug PrescriptionsEducational process of instructingEducational workshopEffectivenessElderlyElectronic Health RecordEmergency SituationEnd stage renal failureEnrollmentEpidemiologic MethodsEpidemiologistEpidemiologyEquipmentEthics CommitteesEthnic OriginEvaluationEventExerciseFacultyFamily PracticeFee-for-Service PlansFeedbackFundingFutureGeographic LocationsGeographyGoalsGoldGovernmentGrantHIVHealthHealth Care Seeking BehaviorHealth PersonnelHealth PolicyHealth ServicesHealth Services ResearchHealth StatusHealth systemHealthcareHealthcare SystemsHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpes Zoster OphthalmicusHerpes zoster diseaseHospitalsHourICD-9ImmunizationImmunocompetenceImmunocompetentImmunocompromised HostImmunosuppressionImmunosuppressive AgentsIncidenceIndividualIndustryInfantInfectionInformaticsInpatientsInstitutesInstitutional Review BoardsInsurance Claim ReviewInterdisciplinary StudyInternationalInternational Classification of DiseasesInterventionK-Series Research Career ProgramsLeadLeadershipLearningLicensureLife Cycle StagesLightLinkLongevityLongitudinal StudiesMalignant NeoplasmsManuscriptsMapsMeasuresMedicalMedicareMedicare Part AMedicare claimMedicineMentorsMentorshipMethodologyMethodsModelingModificationMonitorMulti-Institutional Clinical TrialNorth CarolinaObesityObservation in researchOlder PopulationOpioidOralOrgan TransplantationOutcomeOutcomes ResearchOutpatientsPainParentsParticipantPatientsPatternPeer GroupPeer ReviewPerinatal InfectionPersistent painPersonsPharmaceutical PreparationsPharmacoepidemiologyPharmacologic SubstancePharmacy facilityPoliciesPopulationPopulation HeterogeneityPositioning AttributePostdoctoral FellowPostherpetic neuralgiaPredictive ValuePregnant WomenPreventive healthcarePrimary Health CareProceduresProcessProgram DevelopmentProtocols documentationProxyPublic HealthPublic PolicyPublicationsRaceRandomizedReadingRecombinantsRecommendationRecordsReference StandardsRegulationResearchResearch DesignResearch InstituteResearch MethodologyResearch PersonnelResearch Project GrantsResearch TrainingResourcesRespiratory syncytial virusRiskRisk ManagementRoleRotationSafetySafety ManagementSamplingScienceScientistSecureSeriesServicesSocietiesSolidSpecialistStatistical Data InterpretationStatistical MethodsStreptococcus Group BStructureStudentsStudy SectionSubgroupSubunit VaccinesSyndromeTNFSF15 geneTestingTherapeuticTimeTimeLineTrainers TrainingTrainingTranslatingTranslational ResearchTranslationsTransplant RecipientsUnderrepresented PopulationsUnited StatesUnited States Centers for Medicare and Medicaid ServicesUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesUpdateUse EffectivenessVaccinatedVaccinationVaccine Clinical TrialVaccinesValidationVisitVulnerable PopulationsWomanWorkWorkforce DevelopmentWritingZoster Vaccineage groupbasebeneficiarycareercareer developmentcausal modelchemotherapyclinical Diagnosiscohortcommunity interventioncommunity organizationscomorbiditycomparative effectivenesscomparison groupcongenital immunodeficiencydata accessdata disseminationdata warehousedisabilitydoctoral studenteffectiveness evaluationeffectiveness studyefficacy trialepidemiology studyevidence baseexperiencefaculty mentorfaculty supportfollow-upfrailtygraduate studenthazardhealth care servicehealth care service utilizationhealth datahealth disparityhigh risk populationhuman old age (65+)immunogenicimmunogenicityimprovedindexinginfancyinformatics toolinnovationinpatient serviceinsightinsurance claimsinterestleukemia/lymphomalow income countrymedical schoolsmedication safetymeetingsmemberneonatal infectionnovelnovel vaccinesoutpatient programspandemic diseasepatient health informationpatient subsetspeerpolicy implicationpower analysispreventprimary outcomeprofessorprogramsracial and ethnicreactivation from latencyresearch and developmentresearch studyresponsible research conductrisk minimizationsecondary outcomesexskillsstudy populationsymposiumtraining opportunityvaccination outcomevaccine acceptancevaccine accessvaccine developmentvaccine effectivenessvaccine efficacyvaccine evaluationvaccine safetyvaccine trialvirtualworking group
项目摘要
Abstract/Summary of Parent Award
Since inception in 2008, the UNC CTSA affiliate, the North Carolina Translational and Clinical Sciences Institute
(TraCS) has transformed clinical and translational science at UNC through interdisciplinary research, training,
collaboration with partners and stakeholders, and strong engagement across the CTSA consortium. We have
built a dynamic regional network of universities, research institutes, health care providers, and >130 community
organizations across our state. In the current funding period, we have added NC State University to RTI
International and NC A&T University as full partners in our CTSA hub. In the funding period 2013-2023, our goal
is to translate the best science from UNC and across the CTSA consortium into creative, effective, and accessible
clinical and community interventions, addressing the public health problems of our state and advancing national
CTSA goals. We accomplish through 5 aims: Aim 1. Workforce Development: Develop and support a skilled
and diverse clinical and translational research workforce to advance translational innovations and address
healthcare priorities. Aim 2. Collaboration and Engagement: Engage diverse stakeholders as active partners in
translational research, and promote innovative approaches to team science. Aim 3. Integration: Integrate
translational research across the research continuum, disciplines, populations, and throughout the lifespan. Aim
4. Methods/Processes: Develop and disseminate innovative methods and approaches to address scientific and
operational barriers to translating scientific findings. Aim 5. Informatics: Incorporate cutting-edge informatics
tools and methodologies in every aspect of translational research.
This diversity supplement application by Nadja Vielot, PhD will use real-world Medicare claims data to study
the post-licensure experience in the United States with recombinant herpes zoster vaccine (RZV). The aims of
the proposal are to: 1) Estimate RZV effectiveness against herpes zoster, post-herpetic neuralgia (PHN) and
herpes zoster ophthalmicus (HZO) in adults ages >65, and 2) Estimate the effectiveness of RZV in individuals
with altered immunocompetence. Dr. Vielot will utilize the following CTSA Program resources for the research
and training plan:
Comparative Effectiveness Research: This Service will facilitate the process of securing Medicare data and
oversight of the analyses.
Informatics and Data Science: This Service will be used as part of Aim 3 to obtain data from the Carolina Data
Warehouse for Health (CDW-H) and for assistance in linking CDW-H data to Medicare claims data.
Regulatory Service: Dr. Vielot will use this service for guidance on completing the appropriate IRB and data
use agreements required for the project.
Workforce Development Program: Dr. Vielot will participate in the following WD training opportunities: TraCS
Professional Development Seminar, R Writing Group, Mentor Training, and training in requirements for rigor.
KL2 Program: Dr. Vielot will participate in the K Seminar; a seminar comprised of TraCS-funded KL2
awardees and selected individual K awardees. During this interdisciplinary seminar, she will hone her
communication skills, receive feedback on work in progress including input from clinicians about the potential
clinical and policy implications of her work, identify collaborators for future work, practice peer review skills, and
network with a peer group of interdisciplinary scientists.
TL1 Program: The TraCS TL1 Program consists of 3 tracks, 1 of which supports postdocs who wish to
translate research results into health systems and policy. Dr. Vielot will participate in the TL1 "Tales of
Translation" series which features experts from academia, industry and government discussing pivotal points
in their careers, important research projects, and their views on opportunities and challenges when translating
research results into policy.
In addition, Dr. Vielot will attend either the virtual or in-person annual Translational Science meeting.
摘要/家长奖总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Bernard Buse其他文献
John Bernard Buse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Bernard Buse', 18)}}的其他基金
North Carolina Translational and Clinical Sciences Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
10621596 - 财政年份:2023
- 资助金额:
$ 17万 - 项目类别:
CAMP FHIR: Lightweight, Open-Source FHIR Conversion Software to Support EHR Data Harmonization and Research
CAMP FHIR:支持 EHR 数据协调和研究的轻量级开源 FHIR 转换软件
- 批准号:
10402112 - 财政年份:2021
- 资助金额:
$ 17万 - 项目类别:
ICEES+ COVID-19 Open Infrastructure to Democratize and Accelerate Cross-Institutional Clinical Data Sharing and Research
ICEES COVID-19 开放基础设施民主化并加速跨机构临床数据共享和研究
- 批准号:
10158906 - 财政年份:2020
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational and Clinical Science Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
9986930 - 财政年份:2019
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational and Clinical Science Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
10407956 - 财政年份:2018
- 资助金额:
$ 17万 - 项目类别:
CTSA Administrative Supplement for Quality Assurance/Quality Control Position
CTSA 质量保证/质量控制职位行政补充
- 批准号:
10158836 - 财政年份:2018
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational and Clinical Science Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
9884611 - 财政年份:2018
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational and Clinical Science Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
10585423 - 财政年份:2018
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational and Clinical Science Institute (NC TraCS)
北卡罗来纳州转化与临床科学研究所 (NC TraCS)
- 批准号:
10116521 - 财政年份:2018
- 资助金额:
$ 17万 - 项目类别:
North Carolina Translational & Clinical Sciences Institute (NC TraCS)
北卡罗来纳州翻译
- 批准号:
8743352 - 财政年份:2013
- 资助金额:
$ 17万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 17万 - 项目类别:
Research Grant